These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26228246)

  • 1. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors.
    Hong CW; Chow L; Turkbey EB; Lencioni R; Libutti SK; Wood BJ
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):409-16. PubMed ID: 26228246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
    Tak WY; Lin SM; Wang Y; Zheng J; Vecchione A; Park SY; Chen MH; Wong S; Xu R; Peng CY; Chiou YY; Huang GT; Cai J; Abdullah BJJ; Lee JS; Lee JY; Choi JY; Gopez-Cervantes J; Sherman M; Finn RS; Omata M; O'Neal M; Makris L; Borys N; Poon R; Lencioni R
    Clin Cancer Res; 2018 Jan; 24(1):73-83. PubMed ID: 29018051
    [No Abstract]   [Full Text] [Related]  

  • 3. Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center.
    Yang W; Lee JC; Chen MH; Zhang ZY; Bai XM; Yin SS; Cao K; Wang S; Wu W; Yan K
    J Cancer Res Ther; 2019; 15(4):773-783. PubMed ID: 31436231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin.
    Celik H; Wakim P; Pritchard WF; Castro M; Leonard S; Karanian JW; Dewhirst MW; Lencioni R; Wood BJ
    J Vasc Interv Radiol; 2019 Dec; 30(12):1908-1914. PubMed ID: 31409568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.
    Poon RT; Borys N
    Expert Opin Pharmacother; 2009 Feb; 10(2):333-43. PubMed ID: 19236203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
    Wood BJ; Poon RT; Locklin JK; Dreher MR; Ng KK; Eugeni M; Seidel G; Dromi S; Neeman Z; Kolf M; Black CD; Prabhakar R; Libutti SK
    J Vasc Interv Radiol; 2012 Feb; 23(2):248-55.e7. PubMed ID: 22178041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer.
    Poon RT; Borys N
    Future Oncol; 2011 Aug; 7(8):937-45. PubMed ID: 21823888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model.
    Swenson CE; Haemmerich D; Maul DH; Knox B; Ehrhart N; Reed RA
    PLoS One; 2015; 10(10):e0139752. PubMed ID: 26431204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.
    Lencioni R; Cioni D
    Hepat Oncol; 2016 Aug; 3(3):193-200. PubMed ID: 30191041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of Nonrigid Registration of Pre-Procedure MR with Post-Procedure CT After Radiofrequency Ablation for Hepatocellular Carcinoma.
    Park J; Lee JM; Lee DH; Joo I; Yoon JH; Park JY; Klotz E
    Cardiovasc Intervent Radiol; 2017 Jun; 40(6):873-883. PubMed ID: 28091728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiofrequency Ablation of Liver Tumors: No Difference in the Ablation Zone Volume Between Cirrhotic and Healthy Liver.
    Cassinotto C; Denys A; Gay F; Duran R; Hocquelet A; Piron L; Guiu B
    Cardiovasc Intervent Radiol; 2018 Jun; 41(6):905-911. PubMed ID: 29484466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thermal dose on heat shock protein expression after radio-frequency ablation with and without adjuvant nanoparticle chemotherapies.
    Moussa M; Goldberg SN; Kumar G; Levchenko T; Torchilin V; Ahmed M
    Int J Hyperthermia; 2016 Dec; 32(8):829-841. PubMed ID: 27600101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
    Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
    AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency ablation alone versus radiofrequency ablation combined with chemoembolization in unresectable hepatocellular carcinoma.
    Siriapisith T; Siwasattayanon P; Tongdee T
    J Med Assoc Thai; 2012 Mar; 95(3):430-6. PubMed ID: 22550844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation.
    Kim SS; Kang TW; Kim M; Lee MW; Cho SK; Paik YH; Kim MJ
    Clin Radiol; 2018 Feb; 73(2):216.e1-216.e8. PubMed ID: 28859852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
    Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
    Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone.
    Kim JH; Kim PN; Won HJ; Shin YM
    AJR Am J Roentgenol; 2014 Nov; 203(5):1127-31. PubMed ID: 25341154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound-guided ablative therapy for hepatic malignancies : a comparison of the therapeutic effects of microwave and radiofrequency ablation.
    Zhang XG; Zhang ZL; Hu SY; Wang YL
    Acta Chir Belg; 2014; 114(1):40-5. PubMed ID: 24720137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.